Scott Wolchko | President and Chief Executive Officer |
Ed Dulac | Chief Financial Officer |
Bob Valamehr | Chief Development Officer |
Wayne Chu | Senior Vice President, Clinical Development |
Srikripa Devarakonda | Truist Securities |
Alethia Young | Cantor |
Michael Schmidt | Guggenheim |
Yigal Nochomovitz | Citi |
Mara Goldstein | Mizuho |
Matt Biegler | Oppenheimer |
Carolina Ibanez Ventoso | Stifel |
Biren Amin | Jefferies |
Peter Lawson | Barclays |
Nick Abbott | Wells Fargo |
Welcome to the Fate Therapeutics Fourth Quarter 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section on Fate's Web site at fatetherapeutics.com.
As a reminder, today's call is being recorded. I would now like to introduce Scott Wolchko, President and CEO of Fate Therapeutics.